Description

Compound: Each tablet contains:

Metformin hydrochloride 1000 mg

Auxiliary components: povidone K30, magnesium stearate.

Properties: Metformin is a biguanide with a hypoglycemic effect that reduces both basal and postprandial glucose levels in blood plasma. Does not stimulate insulin secretion and therefore does not cause hypoglycemia. Increases the sensitivity of peripheral receptors to insulin and the utilization of glucose by cells. Reduces the production of glucose by the liver by inhibiting gluconeogenesis and glycogenolysis. Delays the absorption of glucose in the intestine. Metformin stimulates glycogen synthesis by acting on glycogen synthase. Increases the transport capacity of all types of membrane glucose carriers. While taking metformin, the patient’s body weight either remains stable or moderately decreases. Metformin has a beneficial effect on lipid metabolism: reduces total cholesterol, LDL and triglycerides Indications: Type 2 diabetes mellitus, especially in obese patients with diet and exercise failure in adults as monotherapy or in combination with other oral hypoglycemic drugs, or with insulin.

Dosage and administration: Take inside. The tablets are swallowed whole, without chewing, with a sufficient amount of liquid, 1 time per day during or after dinner. The dose of Glucophage XR 1000 mg is selected by the doctor individually for each patient based on the results of measuring the concentration of glucose in the blood. The maximum recommended dose of Glucophage XR 1000 mg is 2 tablets per day (2000 mg). If, when taking the maximum recommended dose 1 time / day, it is not possible to achieve adequate glycemic control, the maximum dose can be divided into two doses: 1 tablet of 1000 mg during breakfast and 1 tablet of 1000 mg during dinner. If adequate glycemic control is not achieved in this case, it is possible to switch to regular release metformin (eg Glucophage film-coated tablets) with a maximum daily dose of 3000 mg.

Contraindications: – hypersensitivity to metformin or to any excipient; -diabetic ketoacidosis, diabetic precoma, coma; – renal failure or impaired renal function (CC less than 45 ml / min); – acute conditions occurring with a risk of developing impaired renal function: – dehydration (with diarrhea, vomiting), severe infectious diseases, shock; – clinically pronounced manifestations of acute or chronic diseases that can lead to the development of tissue hypoxia; – extensive surgeries and injuries; – liver failure, liver dysfunction; -chronic alcoholism, acute alcohol poisoning; -pregnancy; – lactic acidosis; – use for a period of less than 48 hours before and within 48 hours after radioisotope or X-ray studies with the introduction of an iodine-containing contrast agent; -compliance with a hypocaloric diet (<1000 kcal/day); - children's age up to 18 years due to the lack of data on the use.

Precautionary measures: Lactic acidosis is a rare but serious (high mortality in the absence of emergency treatment) complication that can occur due to the accumulation of metformin. Cases of lactic acidosis while taking metformin occurred mainly in patients with diabetes mellitus with severe renal insufficiency.

Side effects: Gastrointestinal disorders: Very often – nausea, vomiting, diarrhea, abdominal pain, lack of appetite. Most often they occur in the initial period of treatment and in most cases resolve spontaneously. Skin and subcutaneous tissue disorders: Very rarely – skin reactions such as erythema, itching, rash. Liver and biliary tract disorders: Very rarely – a violation of liver function tests and hepatitis; after the abolition of metformin, these adverse events completely disappear.

Storage method: Store at a temperature not exceeding 30 degrees.